BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Amicus Therapeutics, Inc. 

1 Cedar Brook Drive

Cranbury  New Jersey  08512  U.S.A.
Phone: 609-662-2000 Fax: 609-662-2001


SEARCH JOBS

View Clinical Trials from BioPharm Insight


Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing novel, first-in-class, small molecules called pharmacological chaperones, to treat human genetic diseases, including lysosomal storage diseases. The Company’s lead pharmacological chaperone migalastat HCl is in Phase 3 as a monotherapy for Fabry disease. Amicus and its partner GlaxoSmithKline Plc (GSK) are conducting Phase 3 registration studies of migalastat HCl for the treatment of Fabry disease. A Phase 3 study intended to support approval of migalastat HCl in the United States is fully enrolled and results are anticipated in the third quarter of 2012. Additionally, Amicus and GSK are currently conducting a separate Phase 3 study intended to further support global registration of migalastat HCl.

Amicus continues to advance its program evaluating the use of pharmacological chaperones in combination with enzyme replacement therapy (ERT) as an expansion of the chaperone technology platform. Two chaperone-ERT combinations, migalastat HCl co-administered with ERT for Fabry disease and AT2220 (duvoglustat HCl) co-administered with ERT for Pompe disease, are currently in Phase 2 development. The Company is also investigating chaperone-ERT combinations for Gaucher disease in preclinical studies.

Amicus also has a preclinical pipeline of pharmacological chaperones for diseases of neurodegeneration, including AT3375 for Parkinson’s disease. The Company has broad, issued intellectual property around the methods, use, and composition of pharmacological chaperones to treat genetic diseases and diseases of neurodegeneration. In addition to the currently issued patents, Amicus has several patent applications pending.


 Key Statistics


Email: info@amicusrx.com
Ownership: Public

Web Site: Amicus Therapeutics, Inc.
Employees: 100
Symbol: FOLD
 









 Company News
Amicus Therapeutics, Inc. (FOLD) To Present At Cowen and Company 35th Annual Health Care Conference 2/26/2015 8:36:27 AM
Amicus Therapeutics, Inc. (FOLD) To Announce Full-Year 2014 Financial Results On March 3, 2015 2/25/2015 8:39:15 AM
Amicus Therapeutics, Inc. (FOLD) Presents Preclinical Data On Next-Generation Pompe ERT At Worldsymposium 2015 2/10/2015 7:47:44 AM
Amicus Therapeutics, Inc. (FOLD) Announces Additional Positive Phase 3 Fabry Data On Patient Reported Outcomes At Worldsymposium 2015 2/10/2015 7:36:21 AM
Amicus Therapeutics, Inc. (FOLD) To Present At Leerink Global Healthcare Conference 2/5/2015 10:35:24 AM
Amicus Therapeutics, Inc. (FOLD) Announces Presentations And Posters At Lysosomal Disease Network WORLD Symposium 1/26/2015 7:42:33 AM
Amicus Therapeutics, Inc. (FOLD) Provides Full-Year 2015 Strategic Outlook And Financial Guidance 1/12/2015 7:39:31 AM
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac Endpoints From Fabry Monotherapy Study 011 And Long Term Extension Study 1/8/2015 7:48:51 AM
Amicus Therapeutics, Inc. (FOLD) To Present Program Updates At 33rd Annual J.P. Morgan Healthcare Conference 12/22/2014 7:42:21 AM
Amicus Therapeutics, Inc. (FOLD) Added To NASDAQ Biotechnology Index (NBI) 12/22/2014 7:39:13 AM
12345678910...